TROP2 scoring and MTAP loss emerge as key biomarkers for NSCLC treatment decisions
Researchers are highlighting two molecular features-TROP2 expression and loss of the MTAP enzyme-as potential guides for therapy in non‑small cell lung cancer.
Quantitative scoring of TROP2 by pathologists, supported by artificial‑intelligence image analysis, can help predict which patients may respond to antibody‑drug conjugates that target this protein.
Loss of MTAP may make tumors vulnerable to specific therapeutic strategies, and identifying this alteration can direct patients toward suitable clinical trials, aiming to personalize treatment and improve outcomes.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss”
read at onclive ↗
comments(0)
5-min edit window · permanent after that